Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial
Jacob Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J.A Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew Buchanan, Na Lu, Andreas Wollenberg
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.